MCID: IND002
MIFTS: 42

Indolent Systemic Mastocytosis malady

Categories: Blood diseases, Rare diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Indolent Systemic Mastocytosis

About this section
Sources:
11Disease Ontology, 13DISEASES, 29ICD10, 30ICD10 via Orphanet, 38MeSH, 44NCIt, 53Orphanet, 61SNOMED-CT, 67UMLS, 68UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Indolent Systemic Mastocytosis:

Name: Indolent Systemic Mastocytosis 11 53 13 67
 
Ism 11

Characteristics:

Orphanet epidemiological data:

53
indolent systemic mastocytosis:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages

Classifications:



External Ids:

Disease Ontology11 DOID:4660
ICD1029 D47.0
MeSH38 D034721
NCIt44 C9286
SNOMED-CT61 397356009, 70910003
Orphanet53 ORPHA98848
ICD10 via Orphanet30 D47.0
UMLS via Orphanet68 C0272203

Summaries for Indolent Systemic Mastocytosis

About this section
MalaCards based summary: Indolent Systemic Mastocytosis, also known as ism, is related to systemic mastocytosis and mastocytosis, and has symptoms including pruritus, abnormality of skin pigmentation and urticaria. An important gene associated with Indolent Systemic Mastocytosis is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways are C-MYB transcription factor network and Regulation of KIT signaling. Affiliated tissues include bone, bone marrow and skin, and related mouse phenotype pigmentation.

Related Diseases for Indolent Systemic Mastocytosis

About this section

Diseases related to Indolent Systemic Mastocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 55)
idRelated DiseaseScoreTop Affiliating Genes
1systemic mastocytosis10.6
2mastocytosis10.6
3corneal granular dystrophy10.4KIT, KITLG
4pericoronitis10.4KIT, KITLG
5movement disease10.3KIT, KITLG
6autosomal recessive non-syndromic intellectual disability10.3KIT, KITLG
7relapsing epidemic typhus10.3KIT, PDGFRA
8asrar facharzt haque syndrome10.3KIT, KITLG
9vagina leiomyosarcoma10.3KIT, PDGFRA
10congenital disorder of glycosylation, type iq10.3KIT, PDGFRA
11malignant biphasic mesothelioma10.3KIT, PDGFRA
12lateral medullary syndrome10.3KIT, PDGFRA
13prostate small cell carcinoma10.3KIT, PDGFRA
14pura syndrome10.2KIT, PDGFRA
15mercaptolactate-cysteine disulfiduria10.2KIT, PDGFRA
16epithelioid leiomyosarcoma10.2KIT, PDGFRA
17pancreatic agenesis10.2KIT, PDGFRA
18multiple spinal canal and spinal cord meningioma10.2KIT, KITLG
19t-b+ severe combined immunodeficiency due to cd3delta/cd3epsilon/cd3zeta10.2KIT, PDGFRA
20multiple chemical sensitivity10.2CD2, KIT
21malignant fibrous histiocytoma of bone10.2KIT, PDGFRA
22multidrug-resistant tuberculosis10.2KIT, PDGFRA
23caroli disease10.2KIT, PDGFRA
24localized osteosarcoma10.1KIT, PDGFRA
25desmoplastic infantile astrocytoma10.1KIT, PDGFRA
26type c thymoma10.1KIT, PDGFRA
27osteoporosis10.1
28angiokeratoma circumscriptum10.1KIT, PDGFRA
29prostate cancer, hereditary, x-linked 110.0KIT, KITLG
30cell type cancer10.0KIT, PDGFRA
31fallopian tube adenosarcoma10.0KIT, PDGFRA
32mastroiacovo de rosa satta syndrome10.0KIT, KITLG, PDGFRA
33cutaneous solitary mastocytoma9.9HDC, KIT, KITLG
34restrictive cardiomyopathy9.9KIT, KITLG, PDGFRA
35loeffler syndrome9.9KIT, KITLG, PDGFRA
36thrombocythemia 39.9KIT, KITLG, PDGFRA
37gallbladder papillomatosis9.9KIT, PDGFRA
38peroxisome biogenesis disorder 7a9.9KIT, KITLG, PDGFRA
39urticaria pigmentosa9.9
40urticaria9.9
41isolated bone marrow mastocytosis9.9
42gastrointestinal stromal tumor9.9KIT, KITLG, PDGFRA
43kala-azar 19.9KIT, KITLG, PDGFRA
44lymphoma9.8
45ileocolitis9.8
46diarrhea9.8
47male reproductive system disease9.8CD2, KIT, PDGFRA
48hemolytic anemia9.8CD2, KIT
49leukemia, acute myeloid9.7CD2, KIT, KITLG
50organ system benign neoplasm9.6CD2, KIT

Graphical network of the top 20 diseases related to Indolent Systemic Mastocytosis:



Diseases related to indolent systemic mastocytosis

Symptoms for Indolent Systemic Mastocytosis

About this section

Human phenotypes related to Indolent Systemic Mastocytosis:

 63 53 (show all 14)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pruritus63 53 hallmark (90%) Very frequent (99-80%) HP:0000989
2 abnormality of skin pigmentation63 53 hallmark (90%) Very frequent (99-80%) HP:0001000
3 urticaria63 53 hallmark (90%) Very frequent (99-80%) HP:0001025
4 sudden cardiac death63 53 hallmark (90%) Very frequent (99-80%) HP:0001645
5 diarrhea63 53 hallmark (90%) Very frequent (99-80%) HP:0002014
6 nausea and vomiting63 53 hallmark (90%) Very frequent (99-80%) HP:0002017
7 abdominal pain63 53 hallmark (90%) Very frequent (99-80%) HP:0002027
8 migraine63 hallmark (90%) HP:0002076
9 impaired temperature sensation63 53 hallmark (90%) Very frequent (99-80%) HP:0010829
10 mastocytosis63 53 hallmark (90%) Very frequent (99-80%) HP:0100495
11 behavioral abnormality63 53 typical (50%) Frequent (79-30%) HP:0000708
12 abnormality of the gastric mucosa63 53 occasional (7.5%) Occasional (29-5%) HP:0004295
13 reduced bone mineral density63 53 occasional (7.5%) Occasional (29-5%) HP:0004349
14 headache53 Very frequent (99-80%)

UMLS symptoms related to Indolent Systemic Mastocytosis:


hepatomegaly, welts

Drugs & Therapeutics for Indolent Systemic Mastocytosis

About this section

Drugs for Indolent Systemic Mastocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1StaurosporineexperimentalPhase 24562996-74-1
24'-N-benzoylstaurosporinePhase 223
3Specific substance maruyamaPhase 214
4Protein Kinase InhibitorsPhase 23612
5Cromolyn SodiumPhase 216
6
Miconazoleapproved, investigational, vet_approved362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
7
Mycophenolate mofetilapproved, investigational939128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
8
Fludarabineapproved111321679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
9
Vidarabineapproved51224356-66-932326, 21704
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
ADENOSINE, U.S.P.
ADN
AI3-52413
AI3-52821
AR-1H6029
ARA-A NSC 247519
Ade-Rib
Adenine Arabinoside
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
Adenosine-8-14C
Adensoine
Ambap5536-17-4
Ara A
Ara-A
Ara-ATP
Araadenosine
Arabinoside Adenine
Arabinoside adenine
Arabinosyl Adenine
Arabinosyl adenine
Arabinosyl-adenine
Arabinosyladenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
Bio1_000437
Bio1_000926
Bio1_001415
Boniton
C00212
CAS-5536-17-4
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
Caswell No. 010B
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
 
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
LS-15059
LS-15085
Lopac0_000123
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC-404241
NSC247519
NSC404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
PDSP1_001036
PDSP2_001020
Pallacor
Polyadenosine
Polyriboadenosine
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
Prestwick_983
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
SPECTRUM1500107
SPECTRUM1500609
SR 96225
SR-96225
STK361815
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spectrum_001894
Spongoadenosine
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
VIRDARABINE
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
adenine-D-ribose
adenosine
alpha-Ara A
beta-Adenosine
beta-Ara A
beta-D-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
10
Mycophenolic acidapproved93924280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
11
Cyclosporineapproved, investigational, vet_approved91579217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
12Dermatologic Agents5674
13Vidarabine Phosphate124
14Immunosuppressive Agents12770
15Antirheumatic Agents10627
16Antifungal Agents3615
17Antibiotics, Antitubercular6972
18Anti-Bacterial Agents10884
19Anti-Infective Agents21402
20Antimetabolites11774
21Antiviral Agents9732
22Antimetabolites, Antineoplastic7171
23Calcineurin Inhibitors1597

Interventional clinical trials:

idNameStatusNCT IDPhase
1A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With HandicapUnknown statusNCT00814073Phase 3
2Study on Mastocytosis for Rupatadine TreatmentCompletedNCT01481909Phase 2, Phase 3
3Midostaurin in Indolent Systemic MastocytosisUnknown statusNCT01920204Phase 2
4Treatment of Indolent Systemic Mastocytosis With PA101CompletedNCT02478957Phase 2
5Efficacy of AB1010 in Patients With Systemic Indolent MastocytosisCompletedNCT00831974Phase 2
6A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002RecruitingNCT02808793Phase 1
7Patient-Reported Outcome Questionnaire for Systemic MastocytosisCompletedNCT02380222
8Mast Cell Connect: A Registry for Patients With MastocytosisRecruitingNCT02620254
9Diagnostic Value of Bone Marrow Tryptase in Systemic MastocytosisRecruitingNCT02441166
10Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciesActive, not recruitingNCT00014235

Search NIH Clinical Center for Indolent Systemic Mastocytosis

Genetic Tests for Indolent Systemic Mastocytosis

About this section

Anatomical Context for Indolent Systemic Mastocytosis

About this section

MalaCards organs/tissues related to Indolent Systemic Mastocytosis:

35
Bone, Bone marrow, Skin, Colon

Animal Models for Indolent Systemic Mastocytosis or affiliated genes

About this section

MGI Mouse Phenotypes related to Indolent Systemic Mastocytosis:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.2KIT, KITLG, PDGFRA

Publications for Indolent Systemic Mastocytosis

About this section

Articles related to Indolent Systemic Mastocytosis:

(show all 44)
idTitleAuthorsYear
1
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis. (27743017)
2017
2
Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. (28069279)
2017
3
Response of patients with indolent systemic mastocytosis to tamoxifen citrate. (26612479)
2016
4
KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression. (26622064)
2016
5
The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis. (25582384)
2015
6
Therapeutic challenge during the long-term follow-up of a patient with indolent systemic mastocytosis with extensive cutaneous involvement. (26004600)
2015
7
Sustained improvement in urticaria pigmentosa and pruritus in a case of indolent systemic mastocytosis treated with cladribine. (25515765)
2015
8
Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression. (26153655)
2015
9
Response to celecoxib in a patient with indolent systemic mastocytosis presenting with intractable diarrhea. (26505934)
2015
10
Serum levels of bone cytokines in indolent systemic mastocytosis associated with osteopenia or osteoporosis. (24439083)
2014
11
Delayed diagnosis of adult indolent systemic mastocytosis. (25386326)
2014
12
MR-based trabecular bone microstructure is not altered in subjects with indolent systemic mastocytosis. (25542754)
2014
13
Indolent systemic mastocytosis in a patient with ileocolitis. (24975749)
2014
14
Endoscopic findings of indolent systemic mastocytosis involving the colon. (25526423)
2014
15
Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis. (24985401)
2014
16
Omalizumab Induced Remission of Idiopathic Anaphylaxis in a Patient Suffering from Indolent Systemic Mastocytosis. (24162824)
2013
17
Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. (24155887)
2013
18
Indolent systemic mastocytosis limited to the bone: a case report and review of the literature. (23903270)
2013
19
Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis. (23621866)
2013
20
KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. (23587333)
2013
21
Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report. (23659595)
2013
22
Prevalence of indolent systemic mastocytosis in a Dutch region. (23219169)
2013
23
Indolent systemic mastocytosis: a case and review of the current available treatment options. (24011312)
2013
24
Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. (23910691)
2013
25
Indolent systemic mastocytosis: is there a reliable radiographic pattern? (22281758)
2012
26
High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. (22229787)
2012
27
Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. (22469616)
2012
28
Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions. (22435702)
2012
29
Indolent systemic mastocytosis treated with narrow-band UVB phototherapy: study of five cases. (21564325)
2012
30
Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. (21193416)
2011
31
Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis. (21454873)
2011
32
Gene expression analysis predicts insect venom anaphylaxis in indolent systemic mastocytosis. (21143240)
2011
33
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. (21782049)
2011
34
Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis. (21208217)
2011
35
Indolent systemic mastocytosis. (20684189)
2010
36
Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. (19541349)
2009
37
High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. (18269681)
2008
38
Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. (18177694)
2008
39
Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease. (18448146)
2008
40
Indolent systemic mastocytosis as the cause of a long history of unexplained hypotensive episodes. (16929885)
2006
41
Use of a doula for labor coaching in a patient with indolent systemic mastocytosis in pregnancy. (16449169)
2006
42
Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. (15722637)
2005
43
Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL. (12688351)
2003
44
Heterogeneity of mast cells in mastocytosis and inhibitory effect of ketotifen and ranitidine on indolent systemic mastocytosis. (9440541)
1997

Variations for Indolent Systemic Mastocytosis

About this section

Expression for genes affiliated with Indolent Systemic Mastocytosis

About this section
Search GEO for disease gene expression data for Indolent Systemic Mastocytosis.

Pathways for genes affiliated with Indolent Systemic Mastocytosis

About this section

Pathways related to Indolent Systemic Mastocytosis according to GeneCards Suite gene sharing:

(show all 22)
idSuper pathwaysScoreTop Affiliating Genes
19.7KIT, KITLG
29.7KIT, KITLG
39.7KIT, KITLG
49.6KIT, PDGFRA
59.6KIT, PDGFRA
6
Show member pathways
9.2KIT, KITLG, PDGFRA
7
Show member pathways
9.2KIT, KITLG, PDGFRA
89.2KIT, KITLG, PDGFRA
99.2KIT, KITLG, PDGFRA
109.2KIT, KITLG, PDGFRA
11
Show member pathways
9.2KIT, KITLG, PDGFRA
129.1CLEC11A, KITLG, PDGFRA
139.1CD2, KIT, KITLG
149.1CD2, KIT, KITLG
15
Show member pathways
9.0CD2, CLEC11A, KITLG
16
Show member pathways
8.7CLEC11A, KIT, KITLG, PDGFRA
17
Show member pathways
8.7CLEC11A, KIT, KITLG, PDGFRA
18
Show member pathways
8.7CLEC11A, KIT, KITLG, PDGFRA
19
Show member pathways
8.7CLEC11A, KIT, KITLG, PDGFRA
20
Show member pathways
8.1CD2, CLEC11A, KIT, KITLG, PDGFRA
21
Show member pathways
8.1CD2, CLEC11A, KIT, KITLG, PDGFRA
22
Show member pathways
8.1CD2, CLEC11A, KIT, KITLG, PDGFRA

GO Terms for genes affiliated with Indolent Systemic Mastocytosis

About this section

Cellular components related to Indolent Systemic Mastocytosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cytoplasmic side of plasma membraneGO:00098989.5CD2, KIT

Biological processes related to Indolent Systemic Mastocytosis according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1embryonic hemopoiesisGO:003516210.3KIT, KITLG
2ectopic germ cell programmed cell deathGO:003523410.2KIT, KITLG
3positive regulation of phospholipase C activityGO:001086310.2KIT, PDGFRA
4positive regulation of phosphatidylinositol 3-kinase activityGO:004355210.1KIT, PDGFRA
5positive regulation of MAP kinase activityGO:00434069.9KIT, KITLG
6positive regulation of phosphatidylinositol 3-kinase signalingGO:00140689.9KIT, PDGFRA
7ovarian follicle developmentGO:00015419.8KIT, KITLG
8positive regulation of DNA replicationGO:00457409.8KITLG, PDGFRA
9cell chemotaxisGO:00603269.7KIT, PDGFRA
10phosphatidylinositol phosphorylationGO:00468549.7KIT, KITLG, PDGFRA
11regulation of phosphatidylinositol 3-kinase signalingGO:00140669.7KIT, KITLG, PDGFRA
12phosphatidylinositol-mediated signalingGO:00480159.6KIT, KITLG, PDGFRA
13MAPK cascadeGO:00001659.2KIT, KITLG, PDGFRA
14positive regulation of cell proliferationGO:00082847.9CLEC11A, KIT, KITLG, MVD, PDGFRA

Molecular functions related to Indolent Systemic Mastocytosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1transmembrane receptor protein tyrosine kinase activityGO:00047149.9KIT, PDGFRA
2phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:00469349.7KIT, KITLG, PDGFRA
3Ras guanyl-nucleotide exchange factor activityGO:00050889.4KIT, KITLG, PDGFRA
4protein homodimerization activityGO:00428038.1CD2, KIT, MVD, PDGFRA

Sources for Indolent Systemic Mastocytosis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet